For research teamsHelp me find a study
Back to all studies
TerminatedNCT00508157

Effects of Aripiprazole Versus Other Atypical Antipsychotics for Metabolic Syndrome; Schizophrenia

This study was terminated in France, in Switzerland, in Belgium, .... It is testing effects of Aripiprazole Versus Other Atypical Antipsychotics for Metabolic Syndrome; Schizophrenia.

Schizophrenia, Metabolic SyndromeDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Aripiprazole may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Aripiprazole, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Belgium, in Czechia, and in France.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNovember 2007
Recruitment status
Terminated
Enrollment listed in the registry
125
Sponsor
Bristol-Myers Squibb
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
France, Switzerland, Belgium, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00508157
Official title
A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Belgium · 1 site
  • Local Institution
    Brussels
    Site status: Not listed — confirm with the team
Czechia · 9 sites
  • Local Institution
    Brno
    Site status: Not listed — confirm with the team
  • Local Institution
    Brno
    Site status: Not listed — confirm with the team
  • Local Institution
    Havířov
    Site status: Not listed — confirm with the team
  • Local Institution
    Hradec Králové
    Site status: Not listed — confirm with the team
  • Local Institution
    Prague
    Site status: Not listed — confirm with the team
  • Local Institution
    Prague
    Site status: Not listed — confirm with the team
  • Local Institution
    Prague
    Site status: Not listed — confirm with the team
  • Local Institution
    Přerov
    Site status: Not listed — confirm with the team
  • Local Institution
    Roudnice nad Labem
    Site status: Not listed — confirm with the team
France · 8 sites
  • Local Institution
    Fains-Véel
    Site status: Not listed — confirm with the team
  • Local Institution
    Lille
    Site status: Not listed — confirm with the team
  • Local Institution
    Limoges
    Site status: Not listed — confirm with the team
  • Local Institution
    Montpellier
    Site status: Not listed — confirm with the team
  • Local Institution
    Paris
    Site status: Not listed — confirm with the team
  • Local Institution
    Paris
    Site status: Not listed — confirm with the team
  • Local Institution
    Poitiers
    Site status: Not listed — confirm with the team
  • Local Institution
    Strasbourg
    Site status: Not listed — confirm with the team
Germany · 2 sites
  • Local Institution
    Ellwangen
    Site status: Not listed — confirm with the team
  • Local Institution
    Werneck
    Site status: Not listed — confirm with the team
Greece · 2 sites
  • Local Institution
    Chania-Crete
    Site status: Not listed — confirm with the team
  • Local Institution
    Corfu
    Site status: Not listed — confirm with the team
Hungary · 2 sites
  • Local Institution
    Budapest
    Site status: Not listed — confirm with the team
  • Local Institution
    Gyula
    Site status: Not listed — confirm with the team
Spain · 4 sites
  • Local Institution
    Oviedo, Principality of Asturias
    Site status: Not listed — confirm with the team
  • Local Institution
    Barcelona
    Site status: Not listed — confirm with the team
  • Local Institution
    Barcelona
    Site status: Not listed — confirm with the team
  • Local Institution
    Barcelona
    Site status: Not listed — confirm with the team
Switzerland · 1 site
  • Local Institution
    Wetzikon
    Site status: Not listed — confirm with the team
Türkiye · 1 site
  • Local Institution
    Izmir
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00508157. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine). Phase 4 studies usually happen after treatment approval, to monitor real-world use.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Bristol-Myers Squibb, which appears to be a pharmaceutical company. Sponsor website: https://www.bms.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.